3 High-Yield Dividend Stocks For The Next Bear Market: GlaxoSmithKline plc, Pearson plc And G4S plc

Should you buy shares in GlaxoSmithKline plc (LON:GSK), Pearson plc (LON:PSON) & G4S plc (LON:GFS) for their dividends?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When stock markets go awry, high yield stocks tend to outperform the broader market. The high-yielding dividend stocks that perform best in a downturn are so-called defensive ones. These are stocks in companies that provide goods and services always needed throughout the business cycle, enabling them to generate stable profits year after year.

Here are three high-yield stocks that could protect your portfolio in a bear market.

Controversial

GlaxoSmithKline (LSE: GSK) may be a controversial pick given its poor earnings trend. But as healthcare needs are continually rising, GSK remains a big growth opportunity. And despite recent weak results, it maintains a strong competitive position and has robust free cash flow generation.

Early signs of recovery are also beginning to show, with quarterly sales figures highlighting strong growth from its new pharmaceutical products, especially its new respiratory drug line-up including recently launched Breo, Anoro and Incruse. New products account for just £2bn in annual sales, but with continued sales growth and additional launches, sales could rise to £6bn by 2018.

Meanwhile, investors are being handsomely rewarded for their patience, with shares in the pharma giant currently yielding 5.5%. There’s one major short-term negative: with the dividend being frozen at 80p per share for 2016 and 2017, there’s no dividend growth for at least two years.

Transition

Pearson (LSE: PSON) is going through a rough patch, reporting a 2% drop in adjusted operating profits in 2015 and management giving a weak set of guidance figures for 2016. Adjusted operating profits are expected to come between £580m and £620m in 2016, which at the mid-point implies a decline of 13% on the previous year.

There are causes for optimism though. Pearson‘s competitive position is strong, and cyclical and policy factors are mainly to blame for recent weakness. This included a buoyant employment market in the US, which meant reduced college enrolment, and policy changes in the UK that lowered demand for its vocational course services.

The outlook in the longer term remains attractive. Pearson has significant exposure to growing markets in Brazil, China, India and South Africa, where it’s launching new products such as the New Student Experience. Its transition from print to digital would also likely be positive to its competitive position, given the advantage scale has on digital platforms.

With an annual dividend of 52p per share, Pearson yields 6%.

Market leader

Investor confidence in G4S (LSE: GFS) is near an all-time low, with the company seemingly embroiled in an endless list of controversies, ranging from overcharging of government contracts, human rights violations and abuse at a young offenders centre. But the company is still set to deliver strong underlying growth in revenues and earnings.

G4S remains global market leader in security services and against the backdrop of global economic uncertainty, demand for its services remains robust. In 2015, it secured new contract sales worth £2.4bn with retention rates near 90%. This shows the company has little trouble in winning new contracts even after recent scandals.

City analysts expect underlying EPS will grow 5.6% this year, to 15.2p per share. For 2017, earnings should climb another 9%, to 16.6p. This would put the shares on an attractive forward P/E of 12.2 and 11.2, respectively.

The stock’s 5.1% yield isn’t as big, but there’s potential for faster future dividend growth, given that earnings growth is set to accelerate.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Tang has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

£500 to invest a month? Consider aiming to turn that into a £20,000 passive income like this!

With a regular monthly investment, it's possible to build a large and steady passive income for retirement. Royston Wild explains.

Read more »

Senior Couple Walking With Pet Bulldog In Countryside
Investing Articles

As retirement needs soar 60%, here’s how I’m building wealth with UK shares

A regular investment in UK shares and funds could help Brits create a large and lasting pension. Our writer Royston…

Read more »

Investing Articles

I’d buy Games Workshop shares before they reach the FTSE 100!

Games Workshop shares look likely to join the FTSE 100 soon. Here’s why I think investors should consider buying the…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Could me buying this stock with a $2.5bn market-cap be like investing in Tesla in 2010?

Archer Aviation (NASDAQ:ACHR) stock's nearly doubled so far in November. Could this start-up be another Tesla in the making?

Read more »

Investing Articles

5,000 shares of this UK dividend stock could net me £1,700 a month in passive income

Our writer calculates the passive income he could earn from holding a significant number of shares in this powerful dividend-paying…

Read more »

Investing Articles

9.3%+ yields! 3 FTSE 100 dividend giants to consider buying

Our writer examines a trio of high-yield FTSE 100 shares and explains some of the opportunities and risks he sees…

Read more »

Investing Articles

As the Kingfisher share price drops on Budget fallout, should I buy?

The Kingfisher share price was on a strong 2024 run until the DIY group warned us of the possible effects…

Read more »

Investing Articles

2 passive income shares to consider for December 2024 onwards?

These are popular UK shares investors often buy for passive income from dividends, but are they actually good investments now?

Read more »